Week Three Assignment Psychopharmacologic Approaches to Treatment of Psychopathology Hispanic Male with MDD Week Three Assignment Psychopharmacologic Approaches to Treatment of Psychopathology Hispani

********** Three AssignmentPsychopharmacologic ********** ** Treatment ** ********************* ***************** *********** ** *************************************** ******* ** **** ***** is ** ******* the case ****** ** ******* Hispanic *** **** ***** ********** ******** ** **** ***** *** ***** ******** ****** during ********* that ******* the *********** prescribed including the *************** and *************** ********* **** ******** ** *** case *** *********** will ***** *** each ******** *** ****** and the ********* ****** ***** ********************************* ** * ******** 32-year-old male **** *** ** **** to ******* **** *** ****** ** * ***** *** ***** his mother had **** This“client ******* **** ** ****** **** **** ** ******** ** ** *** ************ a lot *** being *********** ** high ****** ** ****** that ** *** *** ******* and kept ** himself ** **** reports a ********** ********** interest in ******** ** ***** activities ****** **** ** *** ****** ** ****** ** *** last *** monthsHe ** **** troubled **** ******** ***** ***** ***** *** ****** *** *** *** **** ************* ******* worse ** **** ****** **** ************* ***** ** ******* is getting in “trouble” ** **************** ********* ****** *** *********** Asberg ********** ****** ***** ******* ** 51 *********** ************* Point ***** ******** ***** *** ***** *** ***** choices ** *********** ****** 25 ** ***** ******* ** *** ***** *** ********** ** mg *** * ***** ******* XR 375mg ***** *** *** dosing ******** *** **** ****** ** ********* ********** ** ************** * ******* **** ******* Zoloft and ******* * **** ** get *** most **** *** ** **** Zoloft ** ** **** ***** ******* ** * dual ********* *** ************** ******** **************** 2008) * figure * should ** *** *** gusto *** ***** two neurotransmitters ****** **** *************** medications *** **** ********* efficacies *** safety/tolerability implications ****** ****** and racial ******** *** ***** Latinos were ***** ** **** **** **** ******* **** ***** groups Interethnic differences ** **** ********** ** *** cytochrome ****** ****** *** *********** ******* such variations ** treatment responses ******* *** ***** environmental ******* can ****** ************** ********** ** **** The evidence to **** ****** *** ***** ethnic-specific *********** ** ******** *** ******************* ** newer-generation *************** **** *** ***** ********* *********************** *** ******** ******** & Olfson ************ ** ** “SNRI (dual ********* *** ************** ******** *********** often classified as ** ************** *** ** is *** **** an antidepressant” This ********** **** ****** social ******* and ******* ************* 2008) **** patient ******* social ******** and kept ** ******* **** a **** ***** *** ******* of ******** *** ********** **** ***** ******** ** school The ********** ***** ***** PTSDor ** *** have ********* **** social ******* * **** **** it ******* ** works **** both serotonin *** norepinephrineThe dose choice * was given was ******* ******* ********* ********** guide recommends *** ** *** *** ******** dose which ** * low **** of ******* As *** ******* *** more likely to ****** **** effects I ******* ***** * *** dose *** ******** ***** ******* After **** ***** ** ******* the ******* returns to *** ****** **** ** ****** ** his **************** **** ****** ** **** the Effexor **** **** ** *** same **** ******* *** ******** ** therapeutic ******* is *** ******* immediate *** ***** ******* ***** ************** 2008) **** is *** weeks ****** *** onset *** **** **** ****** He ***** **** **** begun *** ***** ** action"If ** is *** ******* ****** ***** ***** *** ********** it *** ******* a ****** increase or ** *** *** **** ** ************ ***** *** ***** 2008 prescribing ***** mentions **** mirtazapine ** *** best *********** **** *********** **** ****** *** *** a ****** ******* I ** *********** ********* **** obvious * know **** ******** antipsychotics usually **** **** **** *************** but I learned **** from ******** bipolar disorders *********** personality disorders * want ** ***** **** *** ********** from Stahl **** ************** patients **** only a partial ******** ***** some ******** are ******** but others ******* (especially insomnia ******* *** problems *********************** ***** The prescribers ***** **** ****** **** * *** **** ** ****************** the dose ********* ** another ***** or ****** an *********** ********** ******** ****** ***** **** **** **** led ** **** ** the ******************** ************* augmentation *** ************ ** be *********** ** treatment-resistant ********** (TRD) ** ******** **************** (Wang Woo Ahn *** ** ***** **** ***** I ****** ******* **** ******* ** treatment-resistant ******* * ****** ***** ** *** ******* **** or ** ********* **** This ** * ***** ******** * think * will ******** *** dose If **** doesn’t work * will *** ** ******** ************** *** ***** ** ******** ********* **** ********* ****** more **** ******* *** that ***** ****** ** ***** ******* ** **** **** **** ** * solid ***** middle ***** **** * ** ******* **** * ****** **** ***** *** ******** ************* for *** **** of ********** ********** may ** ******** ** the side ******* *********** **** ************* *** **** likely ** ** compliant **** *** course ** ********* ** *********** **** as *** *********** ******* ** *** I am hopeful I ********* killed my patientand ** reports * *** ******** ** symptoms ** ***** ** ************** Although I ** wondering ** he wouldn’t **** **** ****** if * had chosen the ********** ********** *************** ThreeAt this ***** * ** *** want to ******** *** ****** *** **** **** effects that **** ****** in *** ******* ********** treatment ** any **** I am ******** **** ****** ****** ******* ***** to **** the ****** ********* **** *** **** ****************** is * *********** ******** inhibitor *** ******** (D-RIRe)(Stahl ***** ***** ** is risky to mess with *** **** ***************** *** * **** ** ********** *** current ******* and ******** ******* * ** ****** **** *** **** ****** ******* ** enormous *** this patient because ** *** ethnicity *** ******* ************** * ** ***** **** the ********* ** he ****** it **** help **** **** *** I **** ******** **** I **** *** ****** ** ******** **** the **** dosage of the ******* ********************* that *** patient *** **** ******* **** this *** ********** *** eight ***** I ** ********* ** ****** *** choice ** ******* the ****** ******* **** improvement *** still ***** ** **** ***** * **** want *** ******* to ******* ******* ****** ****** wellness For this ******** * am ******** *** WellbutrinWell *** ****** of **** decision would have been * conversation * ***** **** *** ****** ******** ***** * ***** having *** patient’s **** *** have *********** me ** **** **** ** choose * ***** ** exactly **** was recommended ****** ****** ********** ******* *** **** ******* ** increasing *** dosage *** ability to comply with ** ****** ********* and *** ********** ** ****** the ********** drug This ****** would **** ***** me ** **** of ******* or *** the *********** of side effects ** *** additional **** would **** been **** *********** to **** ******* ************ outcomeSummary“Retention ** Hispanics ** *** ********* of *** ***** ********** disorder (MDD) ********* ** ** * major ****** health problem Hispanics **** *** **** treatment *** to ***** times **** ********** than non-Hispanic ****** ******* *** ******** ** ********* ************ *** Hispanics *** ***** *** ***** ** re-entry **** *** ****** ****** **** system” **** **** ***** Psychiatric ********** National ********* ** ****** ****** ******* *** **** ***** *********** Institute ************** **** ****** **** **** effects at ***** ***** and **** ******** than ***** Americans Therefore it ** vitally ********* for *** successful treatment of ***** ********** ******** ** *** ******** **** ** avoid anything **** *** **** ** ************** or **** out of ********* *** **** **** be *** ***** *** **** is ******* *********** ********* ** side ******* with * ****** ********* ****** ** ******* drop out *** still maximize ******* * ******* feel secure **** *** ********* I **** **** the **** *** I am *** satisfied with mediocre *** that I have run ******* this ******** the ***** **** I will *** other ******* **** *** **** until I ******* *** maximum *********** **** the ***** side ****** I ** ******** *** **** ******** ********************************************** ********* (2016g) **** ****** ** ******* ******** *** ********* depressive ******** Interactive Media File ********* ** ******************* R *** A * ******** * ******** * * ***** ****** * ****** ********** ** ** ********** Diagnostic *** ********** Considerations ** ****** ******** Journal ** the American ***** ** ****** Practice 282-296Montgomery * * ****** * *** ********** ***** ******** ** be ********* ** ****** ******* ******* ** ********** *** ********** **** ***** *********** Institute; ******** ********* ** ****** ****** ******* New York ***** *********** ********* ***** **** *** ************* ******* Treatment ****** ** Improve Treatment ********* ** ********* ********* (National Library ** ********* ********* from ******** Trials **** *************************************************** * M ****** Essential Psychopharmacology ******* Prescriber's ***** **** ed) ********* **** *************************************************************************************************************************************************************** * *** * *** * *** IM * * & **** *** (2015) **** HR *** ** AhCan ******** ************* ************ ****** ********** ********* ******* **** Effectively ***** ********* ******** with a Higher Degree ** ********* *********** ************* ******* ** *********************** ***** ********* **** ***********************************************************************************************

Click here to download attached files: docx-(5).docx